Page 22 - பல்கலைக்கழகம் ஆஃப் ஸிந்ஸந்யாடீ கல்லூரி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article NEW YORK, March 17, 2021 /PRNewswire/  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ( UCRI ) to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP).  Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research. We are pleased to commence a new research program with Dr. Hassett and the University of Cincinnati Research Institute, said Robb Knie, CEO of Hoth Therapeutics. There is a growing need for new antibiotic therapies targete

University of cincinnatiUnited statesDaniel hassettRobb knieWalter reed army institute of researchDepartment of molecular geneticsDrug administrationLr advisorsUniversity of cincinnati college medicineHoth therapeutics incUniversity of cincinnati research instituteExchange commissionStanford universityResearch agreementHoth therapeuticsCincinnati research institute